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We present a 53-year-old man with a vocal cord paralysis observed as a primary manifestation of 
lung carcinoma. Tc-99m MDP whole body bone scan were performed and resulted a normal 
scintiscan. The bone scan does not revealed suspicious foci of uptake. The possibility of bone 
metastasis was taken into consideration. A whole body F18-FDG-PET scan showed intense uptake 
in the left upper lung corresponding to the primary tumor.  A bronchial biopsy confirmed 
infiltration by small cell lung carcinoma (SCLC). SCLC is composed of poorly differentiated, 
rapidly growing cells with disease usually occurring centrally rather than peripherally. It 
metastasizes early.  The whole-body F18-FDG-PET scan clearly demonstrated a focus of increased 
uptake in the second lumbar vertebral body suspicious for osteolytic metastasis. A lytic bone 
metastasis was confirmed by MRI. The patient then received therapy and underwent follow up 
abdominal CT. The scan showed blastic changes in the L2 vertebra suggesting response to 
treatment. 
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FIGURE 1. Bone scintigraphy is the method used to screen the whole body for bone metastasis in patients 
with malignancies. We present a 53-year-old man with a 4-month history of progressive dysphonia. Patient 
was referred to a consultant otolaryngologist for clinical examination. Vocal cord paralysis was observed as 
a primary manifestation of left upper lung carcinoma elucidated by chest radiograph. 
Tc-99m MDP whole body bone scan were performed and resulted a normal scintiscan. The bone scan does 
not revealed suspicious foci of uptake. Bone metastasis develop in 30% of all patients with cancer. Bone 
metastases are usually located in the axial skeleton. Scintigraphy does not detect pure lytic metastasis when 
bone turnover is slow or when the site is avascular.  The possibility of bone metastasis should be taken into 
consideration in patients with an underlying cancer history for avoiding delayed or misdiagnosis. 
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FIGURE 2.  A whole body F18 fluorodeoxyglucose (FDG) PET scan showed intense uptake in the left 
upper lung corresponding to the primary tumor  with  a maximum standardized uptake value (SUVmax) of 
19.7 (red arrow). Lung cancer was associated to paratracheal and subcarinal lymph nodes. Pathological 
lymph nodes are clearly demonstrated in clavicular regions (left  SUVmax: 16.7;  and right SUV max:10.4). 
Bronchial biopsy of the upper left lobe confirmed infiltration by small cell lung carcinoma (SCLC). Cancer 
cells expressed: TTF1, CD56, p53, synaptophysin and chromogranin. 
The two main histopathologic categories for lung malignancies are small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC).  In both, its clinical behavior and treatment are different. SCLC accounts 
for the minority (14%) of a lung cancer cases and is composed of poorly differentiated, rapidly growing cells 
with disease usually occurring centrally rather than peripherally. It metastasizes early. Management for 
SCLC is nonsurgical, and therapy is via chemotherapy alone or in combination with radiotherapy.  
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FIGURE 3. The whole-body F18 FDG PET scan clearly demonstrated a focus of increased uptake in the 
second lumbar vertebral body (red cross) which was suspicious for osteolytic metastasis and no other bony 
lesion was identified. An osteolytic bone metastasis was confirmed by MRI. Thus, FDG PET is useful for 
detecting osteolytic metastasis in patients with a malignancy. PET can be a sensitive modality for diagnosing 
and monitoring  bone metastasis. 
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FIGURE 4.  A) Selected axial slice of diagnostic abdominal CT scan, perfomed on March 8, 2011, showed 
the presence of oteolytic metastasis in L2 vertebra (red arrow). B) The patient received radiation therapy and 
chemotherapy. Four weeks later the patient underwent a second follow up CT, and the scan showed blastic 
changes in the posterior edge of the L2 vertebra (red arrow) suggesting response to treatment6. Bone 
metastases are well despicted on CT. But the usefulness of CT in detecting early deposits in bone marrow is 
limited. Although CT is superior to radiography some advanced destructive lesions on trabecular bone may 
not be visible in the absence of cortical bone involvement, so CT is less apparent than the marrow changes 
visualized on MRI. CT is also better than radiography and scintigraphy for depicting lesions in the spine and 
calvarium.  CT is useful in guiding needle biopsy in bones such as vertebrae or ilia.  When assessing the 
therapeutic response, sclerosis of a lytic metastasis on CT suggests a response to treatment. Notwithstanding, 
lysis or the appearance of new lysis or an increase in the size of blastic lesion represents a disease 
progression.  
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